Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Safety Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy for the Treatment of Type 1 Diabetes

NCT01210664 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01210664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01210664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Safety Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy for the Treatment of Type 1 Diabetes
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2010
Completion date
January 31, 2017
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus